Coeptis Therapeutics (COEP) Total Debt to Capital

Coeptis Therapeutics - graphic logo of issuer COEP

Coeptis Therapeutics (COEP) is actively developing personalized methods for combating hematological tumors in the R&D stage. The company's price chart demonstrates the 0.02 indicator. The business relies on external contractors for drug production and the conduct of trials. Simultaneously, the brand is strengthening its image as an innovator by creating platforms to enhance patient immunity in the fight against blood cancer.

Coeptis Therapeutics Inc. (COEP): Debt to Equity Ratio from 04/28/2023 to 05/09/2026

Metric breakdowns and analytics for Coeptis Therapeutics, Inc. (COEP)

- share price and consensus valuation forecast:
Stock Price Coeptis Therapeutics Inc.|COEP - Consensus Target
- market capitalization details:
Market Capitalization Coeptis Therapeutics|COEP - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Coeptis Therapeutics|COEP - Accounting Capitalization|Market Capitalization to Book Value Ratio coeptistx.com|COEP - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Coeptis Therapeutics|COEP - Long-Term Liabilities to Capital|Short-Term Debt to Equity Coeptis Therapeutics Inc.|COEP - Aggregate Debt Obligations|Debt to Book Value Coeptis Therapeutics|COEP - Company Long-Term Loans and Borrowings|Company Short-Term Debts Coeptis Therapeutics|Quick Liquidity coeptistx.com
- net income and valuation ratios data:
COEP - Company Net Income
Fundamental company valuation:Coeptis Therapeutics
Finished products of Coeptis Therapeutics Inc.

This indicator is calculated as the ratio of total liabilities to net equity, reflecting the dependence of operational stability on external financing. For Coeptis Therapeutics (COEP), which develops advanced blood cancer therapies, this debt-to-equity coverage ratio demonstrates the balance between investments in R&D-intensive developments and insolvency risks amid market volatility.

Competitor analysis for Coeptis Therapeutics

TGTX (TG Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Arcellx Inc (ACLX)|Total Debt to Capital IRON|Total Debt to Capital Syndax Corp (SNDX)|Debt to Equity Kura Oncology, Inc. KURA|ADCT: Debt to Equity Ratio|Foghorn - Total Debt to Capital|Vor Biopharma, Inc. (VOR) - Total Debt to Equity Ratio|NKTX: Total Debt to Capital|Debt to Capital Actinium Corp (ATNM)|Debt to Equity Estrella Immunopharma|CASI: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio MRKR (Marker Therapeutics)|INAB (IN8bio Inc.) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Debt to Equity|APTO - Debt to Equity|BPTH: Debt to Equity|MEI Pharma (MEIP) - Debt to Equity|Debt to Capital Vincerx Pharma (VINC)